DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Gusperimus is an investigational drug.
There have been 4 clinical trials for Gusperimus. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2011.
The most common disease conditions in clinical trials are Granulomatosis with Polyangiitis, Nephritis, and Lupus Nephritis. The leading clinical trial sponsors are Nippon Kayaku Co.,Ltd., Nordic Pharma SAS, and [disabled in preview].
There is one US patent protecting this investigational drug and thirteen international patents.
Recent Clinical Trials for Gusperimus
|Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's Granulomatosis||Nordic Pharma SAS||Phase 3|
|Efficacy and Safety of Deoxyspergualin in Renal Transplant Patient With Chronic Rejection||Nippon Kayaku Co.,Ltd.||N/A|
|Phase II Study on Gusperimus in Patients With Refractory Wegener's Granulomatosis||Nippon Kayaku Co.,Ltd.||Phase 2|
Top disease conditions for Gusperimus
Top clinical trial sponsors for Gusperimus
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Gusperimus||See Pricing||Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses||Bristol-Myers Squibb Company (Princeton, NJ)||See Pricing|
|Gusperimus||See Pricing||Heterocyclic compound||Takeda Pharmaceutical Company Limited (Osaka, JP)||See Pricing|
|Gusperimus||See Pricing||Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders||Dana-Farber Cancer Institute, Inc. (Boston, MA)||See Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|